Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.38 |
| ▸ | UGCG | Q16739 | 2/20 | 0.38 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.38 |
| ▸ | SPHK2 | Q9NRA0 | 4/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL131809 | 0.91 | GBA1 (0.33) | GBA1UGCGGBA2SMN1; SMN2ADRB1 | |
| SCHEMBL128458 | 0.89 | GBA1 (0.36) | GBA1UGCGGBA2ADRB1CYP2D6 | |
| SCHEMBL26726817 | 0.84 | GBA1 (0.31) | GBA1UGCGGBA2ADRB1CYP2D6 | |
| SCHEMBL127677 | 0.80 | ALDH1A1 (0.34) | GBA1UGCGGBA2SMN1; SMN2ADRB1 | |
| SCHEMBL16674382 | 0.80 | ALDH1A1 (0.34) | GBA1UGCGGBA2SMN1; SMN2ADRB1 | |
| SCHEMBL14590450 | 0.80 | TSHR (0.38) | GBA1UGCGGBA2SMN1; SMN2TSHR | |
| SCHEMBL22579830 | 0.79 | GBA1 (0.32) | GBA1UGCGGBA2SPHK2SPHK1 | |
| SCHEMBL24607587 | 0.78 | DRD2 (0.39) | GBA1UGCGGBA2SMN1; SMN2 | |
| SCHEMBL21107631 | 0.78 | DRD2 (0.39) | GBA1UGCGGBA2 | |
| SCHEMBL21106043 | 0.77 | PIK3CD (0.43) | GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450319-B2 | Pyrrolopyridazinone compound | UBE INDUSTRIES, LTD. (JP) | 2013-05-28 | — | — | US | disclosed |
| EP-1982986-B1 | PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR | UBE INDUSTRIES (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | UBE INDUSTRIES, LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1982986-A1 | PYRROLOPYRIDAZINONE COMPOUND | Ube Industries, Ltd. (JP) | 2008-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036453-A1 | Pyrrolopyridazinone Compound | CBR3, CBR1, CYC1 | GBA1 1194/4885UGCG 1855/4885GBA2 1577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.